Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial

BACKGROUND: Heterologous vaccine schedules have been recommended to provide superior immunity and protection against emergent SARS-CoV-2 variants of concern. We aimed to evaluate the safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine RQ3013 compared with adenoviral vectored vaccine Ad5...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoqiang, Sun, Zhonghan, Wang, Zhongfang, Chen, Jingjing, Wu, Qianhui, Zheng, Yan, Yang, Xiaoyun, Mo, Luhui, Yan, Xuemei, Li, Wei, Zou, Yanxiang, Song, Huiling, Qian, Feng, Lu, Jing, Zhou, Hui, Wang, Yaping, Xiang, Zuoyun, Yu, Hongjie, Lin, Jinzhong, Yuan, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520343/
https://www.ncbi.nlm.nih.gov/pubmed/37767190
http://dx.doi.org/10.1016/j.eclinm.2023.102231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520343/
https://www.ncbi.nlm.nih.gov/pubmed/37767190
http://dx.doi.org/10.1016/j.eclinm.2023.102231

Ejemplares similares